CrossrefInfokarte
A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors
The Internet Journal of Oncology · 2008
DOI: 10.5580/15d9 ↗Abstract
Kein Abstract verfügbar.
EUVIMED